MX2021013252A - Anticuerpos que se unen a la proteina de circumsporozoito de plasmodium y usos de los mismos. - Google Patents

Anticuerpos que se unen a la proteina de circumsporozoito de plasmodium y usos de los mismos.

Info

Publication number
MX2021013252A
MX2021013252A MX2021013252A MX2021013252A MX2021013252A MX 2021013252 A MX2021013252 A MX 2021013252A MX 2021013252 A MX2021013252 A MX 2021013252A MX 2021013252 A MX2021013252 A MX 2021013252A MX 2021013252 A MX2021013252 A MX 2021013252A
Authority
MX
Mexico
Prior art keywords
circumsporozoite protein
antibodies binding
antibodies
plasmodium circumsporozoite
plasmodium
Prior art date
Application number
MX2021013252A
Other languages
English (en)
Spanish (es)
Inventor
Katja Fink
Luca Piccoli
Davide Corti
Elisabetta Cameroni
Original Assignee
Humabs Biomed Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humabs Biomed Sa filed Critical Humabs Biomed Sa
Publication of MX2021013252A publication Critical patent/MX2021013252A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C07K16/205—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2021013252A 2019-04-30 2020-04-30 Anticuerpos que se unen a la proteina de circumsporozoito de plasmodium y usos de los mismos. MX2021013252A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2019/061135 WO2020221451A1 (en) 2019-04-30 2019-04-30 Antibodies binding to plasmodium circumsporozoite protein and uses thereof
PCT/EP2020/062167 WO2020221910A1 (en) 2019-04-30 2020-04-30 Antibodies binding to plasmodium circumsporozoite protein and uses thereof

Publications (1)

Publication Number Publication Date
MX2021013252A true MX2021013252A (es) 2021-11-17

Family

ID=66429360

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013252A MX2021013252A (es) 2019-04-30 2020-04-30 Anticuerpos que se unen a la proteina de circumsporozoito de plasmodium y usos de los mismos.

Country Status (13)

Country Link
US (1) US20230084102A1 (https=)
EP (1) EP3962513A1 (https=)
JP (1) JP2022531552A (https=)
KR (1) KR20220004055A (https=)
CN (1) CN114206921B (https=)
AU (1) AU2020266283A1 (https=)
BR (1) BR112021016341A2 (https=)
CA (1) CA3130805A1 (https=)
EA (1) EA202192930A1 (https=)
IL (1) IL285282A (https=)
MX (1) MX2021013252A (https=)
SG (1) SG11202108585QA (https=)
WO (2) WO2020221451A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021257665A1 (en) * 2020-06-19 2021-12-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibody that targets a conserved site on the plasmodium falciparum circumsporozoite protein
WO2022251585A2 (en) * 2021-05-28 2022-12-01 David Weiner Dna antibody constructs for use against plasmodium parasites
CN117467005A (zh) * 2023-11-15 2024-01-30 深圳重链生物科技有限公司 抗疟原虫单克隆抗体及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004215125B2 (en) 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
NZ544924A (en) 2003-06-27 2009-03-31 Biogen Idec Inc Modified binding molecules comprising connecting peptides
GB0420634D0 (en) * 2004-09-16 2004-10-20 Glaxosmithkline Biolog Sa Vaccines
EP2158318A2 (en) 2007-05-14 2010-03-03 Biogen Idec MA, Inc. Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
PL2350128T3 (pl) 2008-10-22 2015-03-31 Inst Res Biomedicine Sposoby wytwarzania przeciwciał z komórek plazmatycznych
WO2011022002A1 (en) * 2009-08-18 2011-02-24 The Rockefeller University Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes
US8326547B2 (en) 2009-10-07 2012-12-04 Nanjingjinsirui Science & Technology Biology Corp. Method of sequence optimization for improved recombinant protein expression using a particle swarm optimization algorithm
CN103611151A (zh) * 2013-12-06 2014-03-05 广东药学院 疟原虫环子孢子蛋白多肽CSP I-plus 在制备抗疟疾药物中的应用
WO2018193063A2 (en) * 2017-04-19 2018-10-25 Institute For Research In Biomedicine Novel malaria vaccines and antibodies binding to plasmodium sporozoites

Also Published As

Publication number Publication date
SG11202108585QA (en) 2021-11-29
CA3130805A1 (en) 2020-11-05
US20230084102A1 (en) 2023-03-16
WO2020221451A1 (en) 2020-11-05
AU2020266283A1 (en) 2021-09-02
CN114206921A (zh) 2022-03-18
IL285282A (en) 2021-09-30
EP3962513A1 (en) 2022-03-09
KR20220004055A (ko) 2022-01-11
WO2020221910A1 (en) 2020-11-05
EA202192930A1 (ru) 2022-02-24
CN114206921B (zh) 2024-05-14
BR112021016341A2 (pt) 2021-10-26
JP2022531552A (ja) 2022-07-07

Similar Documents

Publication Publication Date Title
WO2018193063A3 (en) NEW VACCINES AGAINST MALARIA AND ANTIBODIES BINDING PLASMODIUM SPOROZOIDS
GB2532619A (en) Sirp-Alpha Variant Constructs And Uses Thereof
PH12020500671A1 (en) Antibodies specific for gucy2c and uses thereof
MX2016010259A (es) Construcciones de variantes de sirp-alfa y sus usos.
CY1124806T1 (el) Αντισωματα enanti-cd40 και χρησεις αυτων
MX2023001877A (es) Meganucleasas dise?adas especificas para secuencias de reconocimiento en el gen pcsk9.
PH12018501355A1 (en) Rsv f protein mutants
MX2024005946A (es) Polipeptidos que se unen al componente del complemento c5 o albumina serica y proteinas de fusion de los mismos.
PH12019500596A1 (en) Recombinant binding proteins and their use
MX2018000147A (es) Moleculas de anticuerpo que se unen al grupo de diferenciacion 45 (cd45).
EA201891366A1 (ru) Гуманизированные антитела против cd73
WO2015109124A3 (en) Immunomodulatory agents
MX2018000590A (es) Moleculas de anticuerpo que se unen a agrupacion de diferenciacion 79 (cd79).
PH12016501820A1 (en) Il-21 antibodies
MX2021013252A (es) Anticuerpos que se unen a la proteina de circumsporozoito de plasmodium y usos de los mismos.
PH12020550483A1 (en) Anti-apoc3 antibodies and methods of use thereof
WO2020074908A3 (en) Treatment and prevention of malaria based on the antigen pfrh5 and antibodies against the same
MX2021007589A (es) Anticuerpos anti il-36 y procedimientos de uso de estos.
PH12018501739A1 (en) Antibodies for il-17c
MX2022002635A (es) Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso.
WO2019094533A8 (en) Angptl8-binding agents and methods of use thereof
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
MX2023003934A (es) Antigenos de consenso de filovirus, construcciones de acido nucleico y vacunas realizadas a partir de estos, y metodos para utilizarlos.
EP4491227A3 (en) Method for treating multiple sclerosis
ZA202201468B (en) Method